Approximately 46 million people worldwide are living with dementia, and every three seconds someone is diagnosed with the condition. It was originally thought that Alzheimer’s disease disturbs the brain’s immune response, but recent research adds to evidence that inflammation in the brain can in fact drive the development of the disease. The findings of a recent study run at the University of Southampton suggest that by reducing this inflammation, progression of the disease could be halted.
Other neurodegenerative diseases where inflammation has increasingly been seen to pathological role include Parkinson’s Disease, Frontal Lobar Dementia and ALS (amyotrophic laterals sclerosis).
Alkaptonuria is an ultra-rare genetic disorder that causes homogentisic acid to build up in the body. The build-up of homogentisic acid causes the bones and cartilage to become discoloured and brittle. This leads to early onset of a form of chronic osteoarthritis. It is possible that an anti-inflammatory could prove beneficial in alleviating these symptoms.